BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34811896)

  • 21. A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity.
    Cristea MC; Frankel P; Synold T; Rivkin S; Lim D; Chung V; Chao J; Wakabayashi M; Paz B; Han E; Lin P; Leong L; Hakim A; Carroll M; Prakash N; Dellinger T; Park M; Morgan RJ
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):589-598. PubMed ID: 30623229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
    Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
    Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsusaka S; Inokuchi Y; Tanabe S; Kumekawa Y; Koizumi W
    Gastric Cancer; 2017 Mar; 20(2):350-357. PubMed ID: 27189323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer.
    Lee KW; Im SA; Yun T; Song EK; Na Ii; Shin H; Choi IS; Oh DY; Kim JH; Kim DW; Kim TY; Lee JS; Heo DS; Bang YJ; Kim NK
    Jpn J Clin Oncol; 2005 Dec; 35(12):720-6. PubMed ID: 16332718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer.
    Landrum LM; Hyde J; Mannel RS; McMeekin DS; Moore KN; Walker JL
    Gynecol Oncol; 2011 Sep; 122(3):527-31. PubMed ID: 21664657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 and Cisplatin for Gastric Cancer with Peritoneal Metastasis.
    Kobayashi D; Kodera Y; Fukushima R; Morita M; Fushida S; Yamashita N; Yoshikawa K; Ueda S; Yabusaki H; Kusumoto T; Arigami T; Hidemura A; Omori T; Yamaguchi H; Hirono Y; Tsuji Y; Moon JH; Tomita T; Imamura H; Nakanishi K; Shimizu D; Hirakawa A; Ishigami H; Kitayama J
    Ann Surg Oncol; 2024 Feb; 31(2):735-743. PubMed ID: 37952018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer.
    Lu Z; Zhang X; Liu W; Liu T; Hu B; Li W; Fan Q; Xu J; Xu N; Bai Y; Pan Y; Xu Q; Bai W; Xia L; Gao Y; Wang W; Shu Y; Shen L
    Gastric Cancer; 2018 Sep; 21(5):782-791. PubMed ID: 29488121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of intraperitoneal and intravenous chemotherapy for advanced gastric cancer with peritoneal metastasis.
    Chen Y; Wang XJ; Lin RB; Chen L; Lin G; Guo ZQ
    Tumori; 2014; 100(5):e180-8. PubMed ID: 25343556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis.
    Tsimberidou AM; Fu S; Subbiah IM; Naing A; Hong DS; Wen S; Fortier AH; Lim J; Kurzrock R
    Hepatogastroenterology; 2012 Jun; 59(116):960-4. PubMed ID: 22580643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 1 Study of Combined Chemotherapy of Nab-Paclitaxel, S-1, and Oxaliplatin for Gastric Cancer with Peritoneal Metastasis (NSOX Study).
    Nakamura M; Ojima T; Katsuda M; Hayata K; Kitadani J; Nakamori M; Yamaue H
    Oncology; 2021; 99(1):57-61. PubMed ID: 32877909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.
    Kimura Y; Yano H; Imamura H; Fujitani K; Imano M; Tokunaga Y; Matsuoka M; Kurokawa Y; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H
    Jpn J Clin Oncol; 2013 Feb; 43(2):125-31. PubMed ID: 23225911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of SOX combined with intraperitoneal high-dose paclitaxel in gastric cancer with synchronous peritoneal metastasis: A phase II single-arm clinical trial.
    Tu L; Zhang W; Ni L; Xu Z; Yang K; Gou H; Zhu Q; Liu M; Yang Y; Hu J; Qiu M
    Cancer Med; 2023 Feb; 12(4):4161-4169. PubMed ID: 36161282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens.
    Baize N; Abakar-Mahamat A; Mounier N; Berthier F; Caroli-Bosc FX
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):549-55. PubMed ID: 19123051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology.
    Blum Murphy M; Ikoma N; Wang X; Estrella J; Roy-Chowdhuri S; Das P; Minsky BD; Song S; Mansfield P; Ajani J; Badgwell B
    Ann Surg Oncol; 2020 Aug; 27(8):2806-2811. PubMed ID: 31974712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
    Hironaka S; Yamazaki K; Taku K; Yokota T; Shitara K; Kojima T; Ueda S; Machida N; Muro K; Boku N
    Jpn J Clin Oncol; 2010 Nov; 40(11):1014-20. PubMed ID: 20603245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraperitoneal chemotherapy for gastric cancer with peritoneal disease: experience from Singapore and Japan.
    Kono K; Yong WP; Okayama H; Shabbir A; Momma T; Ohki S; Takenoshita S; So J
    Gastric Cancer; 2017 Mar; 20(Suppl 1):122-127. PubMed ID: 27766496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized, Open-Label Phase II Study Comparing Capecitabine-Cisplatin Every 3 Weeks with S-1-Cisplatin Every 5 Weeks in Chemotherapy-Naïve Patients with HER2-Negative Advanced Gastric Cancer: OGSG1105, HERBIS-4A Trial.
    Kawakami H; Takeno A; Endo S; Makari Y; Kawada J; Taniguchi H; Tamura S; Sugimoto N; Kimura Y; Tamura T; Fujitani K; Sakai D; Shimokawa T; Kurokawa Y; Satoh T
    Oncologist; 2018 Dec; 23(12):1411-e147. PubMed ID: 30115736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer.
    Kim C; Lee JL; Choi YH; Kang BW; Ryu MH; Chang HM; Kim TW; Kang YK
    Invest New Drugs; 2012 Feb; 30(1):306-15. PubMed ID: 20839031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Intraperitoneal Chemotherapy for Peritoneal Metastasis of Gastric Cancer].
    Yamaguchi H; Ishigami H; Kitayama J
    Gan To Kagaku Ryoho; 2016 Dec; 43(13):2481-2485. PubMed ID: 28028253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.
    Chambers SK; Chow HH; Janicek MF; Cragun JM; Hatch KD; Cui H; Laughren C; Clouser MC; Cohen JL; Wright HM; Abu Shahin N; Alberts DS
    Clin Cancer Res; 2012 May; 18(9):2668-78. PubMed ID: 22421191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.